Congress trades
GSK plc (GSK)
About GSK plc
from the company's filings and listing- Exchange
- NYSE
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Chief executive
- Luke Victor Miels
- Employees
- 66,841
- Listed since
- Mar 28, 1980
- Market value
- $97.4B
- Price to earnings
- 14.9
- Earnings per share
- $2.40
- Dividend yield
- 3.79%
Earnings
6 reported quarters · next on Oct 28, 2026| Quarter | EPS | EPS expected | Revenue | Revenue expected | Result |
|---|---|---|---|---|---|
| Jul 28, 2026 | $1.36 | $1.27 | $11.2B | $11.0B | EPS beatRevenue in line |
| Q1 FY2026reported Apr 29, 2026 | $1.24 | $1.16 | $10.3B | $10.2B | EPS beatRevenue in line |
| Q4 FY2025reported Feb 4, 2026 | $0.68 | $0.64 | $11.8B | $11.4B | EPS beatRevenue beat |
| Q3 FY2025reported Oct 29, 2025 | $1.48 | $1.26 | $11.3B | $11.0B | EPS beatRevenue beat |
| Q2 FY2025reported Jul 30, 2025 | $1.23 | $1.12 | $10.6B | $10.5B | EPS beatRevenue in line |
| Q1 FY2025reported Apr 30, 2025 | $1.13 | $1.08 | $10.0B | $9.7B | EPS beatRevenue beat |
Actual against the consensus estimate at the time. A flag marks a beat or a miss of more than 1.5% either way; inside that band the quarter is in line. A flag marked GAAP compares a GAAP figure the company reported with an adjusted consensus, two different measures, so a one-time gain or charge can move it either way; basis unverified means we could not classify the reported figure. A flag reads n/a only when a number is missing. An estimate is a forecast made by analysts, not a company target.
Institutional holders
13F positions as of Jun 30, 2026| Holder | Value | Shares | Change | Of company |
|---|---|---|---|---|
| FMR LLC | $3.4B | 64,961,641 | -4.0% | 3.24% |
| Dodge & Cox | $2.5B | 48,197,514 | -17.8% | 2.40% |
| Fisher Asset Management, LLC | $1.9B | 35,722,792 | +3.5% | 1.78% |
| Primecap Management Co | $1.3B | 25,182,068 | -0.1% | 1.25% |
| Wellington Management Group LLP | $597.4M | 11,396,249 | -2.7% | 0.57% |
| JTC Employer Solutions Trustee Ltd | $450.3M | 8,592,987 | -5.0% | 0.43% |
| Morgan Stanley | $401.4M | 7,657,562 | -30.6% | 0.38% |
| Royal Bank Of Canada | $397.8M | 7,588,928 | +1.1% | 0.38% |
| Price T Rowe Associates Inc | $362.9M | 6,923,642 | -5.5% | 0.34% |
| Acadian Asset Management LLC | $349.1M | 6,660,434 | -43.5% | 0.33% |
| Goldman Sachs Group Inc | $334.0M | 6,371,442 | -33.6% | 0.32% |
| State Street Corp | $315.1M | 5,959,115 | -0.7% | 0.30% |
A 13F reports long US equity positions 45 days after the quarter ends, so these are positions as they stood on Jun 30, 2026. For a manager's whole book see the fund directory.
GetSignal watches Form 4 and STOCK Act filings and pushes each one to your phone as it is published, with the history behind it. Free on iOS and Android.
Congress trades in GSK
20 disclosures of 62 on record · median 34d of the 45 allowed| Member | Type | Action | Amount disclosed | Since the trade | Trade date | Disclosed | Delay |
|---|---|---|---|---|---|---|---|
| Lisa C. McClainSpouse | Stock | Sale | $1,001 - $15,000 | +3.8%S&P +11.8% · vs S&P 500 -8.0% | Oct 31, 2025 | Nov 21, 2025 | 21d |
| Lisa C. McClainSpouse | Stock | Sale | $1,001 - $15,000 | +4.1%S&P +12.3% · vs S&P 500 -8.2% | Oct 30, 2025 | Nov 21, 2025 | 22d |
| Lisa C. McClain | Stock | Purchase | $1,001 - $15,000 | n/a | Oct 30, 2025 | Nov 21, 2025 | 22d |
| Val T. HoyleSpouse | Stock | Sale | $1,001 - $15,000 | +20.0%S&P +14.6% · vs S&P 500 +5.4% | Sep 23, 2025 | Oct 10, 2025 | 17d |
| Lisa C. McClainSpouse | Stock | Purchase | $1,001 - $15,000 | +29.7%S&P +21.0% · vs S&P 500 +8.7% | Aug 4, 2025 | Sep 12, 2025 | 39d |
| Val T. HoyleSpouseFiled late | Stock | Purchase | $1,001 - $15,000 | +44.4%S&P +29.6% · vs S&P 500 +14.7% | Nov 18, 2024 | Sep 12, 2025 | 298d |
| Robert B. Aderholt | Stock | Sale | $1,001 - $15,000 | +29.9%S&P +19.7% · vs S&P 500 +10.1% | Jul 28, 2025 | Sep 10, 2025 | 44d |
| Lisa C. McClainSpouseFiled late | Stock | Purchase | $1,001 - $15,000 | +23.0%S&P +27.8% · vs S&P 500 -4.8% | Jun 17, 2025 | Aug 13, 2025 | 57d |
| Lisa C. McClainSpouseFiled late | Stock | Sale | $1,001 - $15,000 | +26.3%S&P +25.5% · vs S&P 500 +0.9% | Jun 24, 2025 | Aug 13, 2025 | 50d |
| Bruce Westerman | Stock | Sale | $1,001 - $15,000 | +33.4%S&P +48.4% · vs S&P 500 -15.0% | Apr 21, 2025 | May 12, 2025 | 21d |
| Bruce Westerman | Stock | Purchase | $1,001 - $15,000 | +28.1%S&P +30.5% · vs S&P 500 -2.4% | Mar 3, 2025 | Apr 16, 2025 | 44d |
| Marjorie Taylor Greene | Stock | Purchase | $1,001 - $15,000 | +42.4%S&P +27.6% · vs S&P 500 +14.8% | Nov 25, 2024 | Nov 27, 2024 | 2d |
| Tommy TubervilleJoint | Stock | Sale (Full) | $1,001 - $15,000 | +32.9%S&P +75.0% · vs S&P 500 -42.0% | Oct 16, 2023 | Nov 16, 2023 | 31d |
| Daniel S. Goldman | Stock | Sale | $15,001 - $50,000 | +43.7%S&P +73.5% · vs S&P 500 -29.8% | Jul 10, 2023 | Aug 13, 2023 | 34d |
| Tommy TubervilleJoint | Stock | Purchase | $1,001 - $15,000 | +35.3%S&P +85.6% · vs S&P 500 -50.4% | Apr 3, 2023 | May 11, 2023 | 38d |
| Virginia FoxxJoint | Stock | Sale | $50,001 - $100,000 | +41.9%S&P +93.2% · vs S&P 500 -51.2% | Mar 1, 2023 | Apr 4, 2023 | 34d |
| Virginia FoxxJoint | Stock | Purchase | $1,001 - $15,000 | +37.9%S&P +77.4% · vs S&P 500 -39.5% | Aug 16, 2022 | Sep 8, 2022 | 23d |
| Virginia FoxxJoint | Stock | Purchase | $15,001 - $50,000 | +27.0%S&P +81.5% · vs S&P 500 -54.6% | Aug 10, 2022 | Sep 8, 2022 | 29d |
| Virginia FoxxJoint | Stock | Purchase | $1,001 - $15,000 | +21.5%S&P +85.4% · vs S&P 500 -63.9% | Aug 9, 2022 | Sep 8, 2022 | 30d |
| Virginia FoxxJoint | Stock | Purchase | $15,001 - $50,000 | +19.9%S&P +84.5% · vs S&P 500 -64.6% | Aug 5, 2022 | Sep 8, 2022 | 34d |
Since the trade: the stock's move from the trade date to the latest close we hold, as of Sep 10, 2026, an estimate, with the S&P 500 over the same window and the difference against it. The figures describe the stock after the trade, not the member's result: the filing carries a band, not a fill, and a sale keeps the same sign, so a positive figure after a sale means the stock kept rising. An option row carries the underlying stock's move. A row marked n/a has no market price. Not investment advice.
Members of Congress reporting a position
3 members · estimate, as of Sep 10, 20263 members report a position (estimated). The largest estimated position is in the $50,001 - $100,000 band.
| Member | Party, chamber | Estimated position | Share of their portfolio |
|---|---|---|---|
| Harriet M. Hageman | Republican · House | $50,001 - $100,000 | 2.5% |
| Steve Cohen | Democrat · House | $15,001 - $50,000 | 0.9% |
| Marjorie Taylor Greene | Republican · House | $1,001 - $15,000 | 0.3% |
Estimate, as of Sep 10, 2026. Each position is modelled from the member's disclosed transactions and annual filings: the midpoint of each disclosed band, moved with the stock's price since the trade. It is a rough estimate of a reported position, not a figure from a filing, which is why it is shown as a band. Share of portfolio sets that estimate against the member's whole estimated public-stock portfolio.
Questions
Which members of Congress have traded GSK?
Lisa C. McClain, Val T. Hoyle, Robert B. Aderholt, Bruce Westerman, Marjorie Taylor Greene, Tommy Tuberville and others disclosed GSK transactions in the filings shown here.
Which members of Congress hold GSK?
3 members of Congress report a position in GSK in the estimate we hold as of Sep 10, 2026. The three largest estimated positions belong to Harriet M. Hageman, Steve Cohen and Marjorie Taylor Greene. The estimate is built from disclosed transactions and annual filings, so it is shown as a band rather than a figure from a filing.
How quickly are GSK trades disclosed?
Congressional disclosures took a median of 34 days, against the 45 the STOCK Act allows.
How to read a STOCK Act filing
WHAT THE FILING ACTUALLY SAYS
Congress rows disclose a value range rather than an exact amount, and the STOCK Act allows up to 45 days to report. Full sourcing and the limits of this data are on the methodology page. A filing is a record of a transaction, not a signal, and nothing here is investment advice.
Data as of Sep 10, 2026.